1-3 of 3
Thomas Hofer, PhD
Close
Sort by
Journal Articles

Modelling Single Cell B-Cell Receptor Signaling Reveals Enhanced Activity in Primary CLL Cells Compared to Non-Malignant Cells While Fundamental Network Circuit Topology Remains Stable Even with Novel Therapeutic Inhibitors

Daniel Mertens, PhD, Christine Wolf, PhD, Carsten Maus, PhD, Michael Persicke, Katharina Filarsky, PhD, Hartmut Döhner, Peter Lichter, PhD, Thomas Höfer, PhD, Stephan Stilgenbauer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4275.
https://doi.org/10.1182/blood-2019-127837
Published: 2019
Journal Articles

GVHD Is Sustained By T Cell Maintenance within Target Tissues: Insights from Clonal Tracking and Parabiosis

Faruk Sacirbegovic, PhD, Sarah T Rosenberger, MS, Daqiang Zhao, MD PhD, Matthias Günther, PhD, Martin H Oberbarnscheidt, MD PhD, Fadi G Lakkis, MD, Thomas Höfer, PhD, Warren D Shlomchik, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 809.
https://doi.org/10.1182/blood-2018-99-119134
Published: 2018
Journal Articles

Novel Tumor-Targeted, Engineered IL-2 Variant (IL2v)-Based Immunocytokines For Immunotherapy Of Cancer

Christian Klein, PhD, Inja Waldhauer, PhD, Valeria Nicolini, PhD, Claire Dunn, PhD, Anne Freimoser-Grundschober, PhD, Gerrits Danny, PhD, Otto Boerman, PhD, Tapan Nayak, PhD, Sylvia Herter, PhD, Erwin Van Puijenbroek, Oliver Ast, PhD, Thomas Hofer, PhD, Ralf Hosse, Sabine Lang, Sebastian Neumann, Hubert Kettenberger, Markus Neubauer, Ingo Gorr, Dietrich Tuerck, Stefan Evers, Christian Gerdes, Victor Levitsky, Marina Bacac, Ekkehard Moessner, Pablo Umana, PhD
Journal: Blood
Blood (2013) 122 (21): 2278.
https://doi.org/10.1182/blood.V122.21.2278.2278
Published: 2013